1	Innate lymphoid cells are activated and their levels correlate with viral load in patients
2	with Puumala hantavirus caused hemorrhagic fever with renal syndrome.
3	
4	Short title: Innate lymphoid cells in hemorrhagic fever with renal syndrome
5	
6	Author list: Marina García ^a , Anna Carrasco García ^a , Johanna Tauriainen ^a , Kimia Maleki ^a ,
7	Antti Vaheri ^b , Satu Mäkelä ^{d,e} , Jukka Mustonen ^{d,e} , Anna Smed-Sörensen ^c , Tomas Strandin ^{b,c} ,
8	Jenny Mjösberg ^{a#} , Jonas Klingström ^{a#} .
9	
10	Affiliations
11	^a Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet,
12	Stockholm, Sweden
13	^b Department of Virology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
14	^c Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet,
15	Karolinska University Hospital, Stockholm, Sweden.
16	^d Department of Internal Medicine, Tampere University Hospital, Tampere, Finland
17	^e Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
18	#Equal contribution
19	
20	Corresponding authors. Dr. Jenny Mjösberg and Dr. Jonas Klingström
21	e-mail: jenny.mjosberg@ki.se
22	e-mail: jonas.klingstrom@ki.se
23	
24	Keywords: Innate lymphoid cells, NK cells, hantavirus, orthohantavirus, hemorrhagic fever
25	with renal syndrome, viral load
26	NOTE. This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 ABSTRACT

Background. Innate lymphoid cells (ILCs) are involved in immunity and homeostasis but, except for natural killer (NK) cells, their role in human viral infections is not well known. Puumala virus (PUUV) is a hantavirus that causes the acute zoonotic disease hemorrhagic fever with renal syndrome (HFRS). HFRS is characterized by strong systemic inflammation and NK cells are highly activated in HFRS, suggesting that also other ILCs might be responding to infection.

34 **Methods.** Here we phenotypically analyzed peripheral ILCs in acute and convalescent 35 PUUV-infected HFRS patients. Additionally, plasma levels of soluble factors and viral load 36 were analyzed.

Findings. Overall, the frequencies of NK cells and naïve ILCs were reduced while the 37 38 frequency of ILC2, in particular the ILC2-lineage committed c-Kit^{lo} ILC2 subset, was 39 increased during acute HFRS. Interestingly, we observed a negative correlation between viral 40 load and frequencies of both NK and non-NK ILCs in acute HFRS. Phenotypically, ILCs 41 displayed an activated profile with increased proliferation, and showed altered expression of 42 several homing markers during acute HFRS. In line with the observation of activated ILCs, 43 plasma levels of inflammatory proteins, including the ILC-associated cytokines interleukin 44 (IL)-13, IL-23, IL-25, IL-33, and thymic stromal lymphopoietin (TSLP), were elevated during 45 acute HFRS.

46 Interpretation. These findings indicate a general involvement of ILCs in response to human 47 hantavirus infection. Further, this constitutes the first comprehensive study of ILCs in a 48 hantavirus-caused disease, aiding in further understanding the role of these cells in disease 49 pathogenesis and in human viral infections in general.

Funding. A full list of funding bodies that contributed to this study can be found in theAcknowledgements section.

52 **RESEARCH IN CONTEXT**

53 Evidence before this study

54 Innate lymphoid cells (ILCs) include a broad range of innate cell subsets involved, among 55 other functions, in early response to infections. Natural killer (NK) cells have been broadly 56 characterized in human viral infections, but much less is known in such context about other 57 more recently discovered ILCs. Puumala virus is one of the causative agents of hemorrhagic 58 fever with renal syndrome (HFRS), an acute zoonotic disease characterized by systemic 59 inflammation. No current treatment or vaccines are available to date for hantavirus-caused diseases and pathogenesis is still not fully understood. A PubMed search up until April 2022 60 61 using a combination of the terms virus, Puumala virus, hantavirus, HFRS, ILCs, and NK cells 62 shows that while studies have been performed characterizing NK cells in HFRS, no studies are available on the rest of ILCs in hantavirus-caused diseases, which in addition have been 63 64 studied in only a handful of human viral infections.

65 Added value of this study

In this study we thoroughly characterized the ILC landscape in circulation and its milieu in 66 acute and convalescent Puumala-infected HFRS patients. We found that the frequency of NK 67 68 cells and other ILC subsets was altered in the acute HFRS patients as compared to 69 convalescent HFRS patients and control individuals, with a decrease in NK cells and naïve 70 ILCs, and an increase in ILC2. In particular the ILC2-lineage committed c-Kitlo ILC2 subset 71 was found increased. Total ILCs showed increased levels of activation and proliferation, and 72 signs of altered migration patterns in acute HFRS patients. The finding of elevated levels of 73 several soluble inflammatory proteins associated with ILCs in acute HFRS patients further 74 suggests an implication of ILCs in HFRS. Moreover, an association between the frequency of 75 NK cells and non-NK ILCs and plasma viral load suggest a possible connection between viremia and the activity of these cell types during the course of disease. 76

77 Implications of all the available evidence

78	Our researc	ch shows	that all circulation	ing ILCs, including	non-NK ILCs,	are activated,
79	proliferating	g, and corr	elate with viral	load in acute HFRS	patients, indica	ating a general
80	involvemen	t in human	hantavirus infect	ion and disease. Being	g the first comp	ehensive study
81	on ILCs in	hantavirus	infections, furthe	er research will give re	elevant insight in	nto the roles of
82	ILCs	in	disease	pathogenesis	and	protection.

83 INTRODUCTION

84 Innate lymphoid cells (ILCs) are a group of innate immune cells that play important roles in the modulation of immune and inflammatory responses.¹ Naïve ILCs (nILC) constitute an 85 immature subset ^{2,3} that can home from peripheral blood to tissues where they give rise to the 86 mature ILC subsets ⁴. Mature ILCs are classified in five main subsets based on the 87 88 transcription factors they express and the cytokines they produce: natural killer (NK) cells, ILC1, ILC2, ILC3, and lymphoid tissue inducer (LTi) cells.^{5,6} NK cells share the same 89 90 features as ILC1, but in addition can, as opposed to the other ILCs, kill virus-infected cells.⁶ 91 ILC1 and ILC3 are mainly found in mucosal tissues while NK cells and ILC2 are found both in tissues and in peripheral blood.^{2,4} Furthermore, two functionally distinct subsets of ILC2 92 can be found in peripheral blood: c-Kit^{lo} and c-Kit^{hi} ILC2, the first being more committed to 93 the ILC2 lineage.⁷ 94

NK cells have been extensively described in different viral infections.^{8–10} On the other 95 hand, non-NK ILCs (hereinafter referred to as ILCs) were more recently discovered,^{11,12} and 96 97 thus less is known regarding their role in viral infections. Due to their location in mucosal 98 tissue, ILCs are on the first line of defense and hence potentially essential in the early phases 99 of viral infections.¹³ Their enrichment in lungs suggests an important role for ILCs in respiratory viral infections.^{13,14} There are conflicting data regarding ILC2 and virus infections: 100 101 they have been suggested to promote tissue repair and protect the lungs of influenza-infected mice,^{15,16} while other studies reported that ILC2 induce airway hyperreactivity in influenza-102 infected ¹⁷⁻¹⁹ and respiratory syncytial virus-infected ²⁰ mice. Furthermore, ILCs have 103 104 recently been investigated in the context of a few human viral diseases. In HIV-1 infected individuals, levels of ILCs were found to be reduced in ileum and colon, ²¹ as well as in 105 106 circulation, and to negatively correlate with viral load.²² Total peripheral ILC levels were also 107 found to be decreased in SARS-CoV-2-infected coronavirus disease-19 (COVID-19) patients,

108 with ILC2 decreased in severe but not in moderate patients.^{23–25} Moreover, in infants with 109 respiratory syncytial virus bronchiolitis, elevated levels of ILC2 in the airways were found to 110 associate with disease severity.²⁶ Overall, these studies show an effect of viral infections on 111 the ILC landscape.

112 Hantaviruses (genus Orthohantavirus, family Hantaviridae, order Bunyavirales) are RNA viruses that can cause zoonotic diseases in humans²⁷. The reservoirs of disease-causing 113 114 hantaviruses are rodents, and humans are normally infected via inhalation of hantavirusinfected rodent excreta.^{28,29} Hantaviruses can cause hemorrhagic fever with renal syndrome 115 116 (HFRS) in Eurasia and hantavirus pulmonary syndrome (HPS) in the Americas, with up to 10% and around 35% case fatality rate, respectively.^{28,30,31} Puumala virus (PUUV) is endemic 117 in Europe, where it is the most common causative agent of HFRS.^{30,32} Hantavirus-infected 118 119 patients initially develop non-specific symptoms such as high fever and headache, and many 120 eventually present kidney dysfunction (primarily in HFRS), lung dysfunction (primarily in 121 HPS), and gastrointestinal symptoms, including abdominal pain, diarrhea, vomiting, and gastrointestinal bleeding.^{31,33,34} As of today, no specific treatment nor United States Food and 122 123 Drug Administration / European Medicines Agency-approved vaccines are available for hantavirus-caused diseases.35 Hantaviruses trigger immunopathogenic responses that likely 124 contribute to hyperinflammation ^{36–43} and vascular leakage in patients, but the exact 125 mechanisms leading to these events remain to be understood.^{32,44,45} Peripheral NK cells show 126 signs of strong activation and proliferation in the acute phase of HFRS.⁴⁶⁻⁴⁹ B and T cells are 127 128 highly expanded in the circulation of HFRS and HPS patients, with concomitant elevated levels of CD8⁺ T cells in the respiratory airways, ^{36,50–54}. Mucosa-associated invariant T 129 130 (MAIT) cells were recently shown to be reduced but highly activated in circulation during 131 PUUV-caused HFRS.⁴² Levels of neutrophils are highly increased and also strongly activated in hantavirus-infected patients.55-57 Mononuclear phagocytes are susceptible to infection with 132

hantaviruses, and their activation and redistribution from circulation towards the airways and
kidneys in HFRS patients have been reported.^{58–61} Combined, these reports show that
hantaviruses trigger strong immune cell responses, indicating a possible involvement of ILCs
as well.

137 Here we performed a detailed characterization of peripheral blood ILCs and NK cells, 138 as well as of their cytokine and chemokine milieu, in PUUV-infected HFRS patients. We 139 observed increased plasma levels of inflammatory proteins, including ILC-associated 140 cytokines. We showed that NK cell frequencies are reduced during acute HFRS but recover 141 during convalescence. While total ILC frequencies did not change, we report increased 142 frequency of ILC2 and a concomitant decreased frequency of nILC during acute HFRS. In 143 particular, the ILC2-lineage committed c-Kit^{lo} ILC2 subset was increased during acute HFRS. 144 Furthermore, NK cells and ILCs displayed an activated phenotype and ongoing proliferation 145 during acute HFRS. Interestingly, we observed a negative correlation between viral load and 146 the frequencies of both NK cells and ILCs in acute HFRS, suggesting a potential direct or 147 indirect influence of hantaviruses on the ILC landscape in HFRS patients.

148

149 MATERIAL AND METHODS

150 **Patient samples**

151 17 patients with serologically confirmed acute HFRS were included in the study. The patients 152 were diagnosed with PUUV infection at the Tampere University Hospital, Finland during 153 2002–2007. Whole blood samples were collected, and peripheral blood mononuclear cells 154 (PBMCs) were isolated as previously described and stored in liquid nitrogen at -150°C, while 155 plasma was stored at -80°C, until further use. ⁶¹

156 The study was approved by the Ethics Committee of Tampere University Hospital 157 (ethical permit nr. R04180) and all subjects gave written informed consent. The samples were

158 collected in the acute phase of disease (5-8 days after onset of symptoms), during the early 159 convalescence phase (20-27 days after onset of symptoms), and at a late convalescence phase 160 at 180 or 360 days after onset of symptoms. Patients were stratified as having either mild or 161 severe HFRS based on a scoring system adapted from the sequential organ failure assessment 162 scoring system, where the maximum levels of creatinine (4 = > 440, 3 = 300-440, 2 = 171-299, 1 = 110-170, and 0 = $< 110 \mu mol/l$), minimum level of platelets (4 = < 20, 3 = 20-49, 2 =163 164 50-99, 1 = 100-150, and 0 = > 150 x $10^{3}/\mu$ l), and minimum mean arterial blood pressure (1 = 165 < 70 and $0 = \ge 70$ mmHg) were ranked. A total score of ≥ 5 was considered severe and < 5mild. 61,62 166

As controls, PBMCs were obtained from buffy coats from 10 healthy blood donors from the Blood Transfusion Clinic at the Karolinska University Hospital Huddinge, Stockholm, Sweden (ethical permit nr. 2020-02604) and stored in liquid nitrogen until further use. PBMCs were isolated from the buffy coats by density centrifugation using Lymphoprep (StemCell Technologies), according to manufacturer's guidelines.

172

173 Viral load in plasma

RNA was isolated from 140 μl of patient EDTA-plasma using column-based RNA isolation
kit following the manufacturer's instructions (Viral RNA mini kit, Qiagen). Isolated RNA
was subjected to PUUV S RNA RT-qPCR analysis based on a previously described
protocol,⁶³ with TaqMan fast virus 1-step master mix (Thermo Scientific) using AriaMx
instrumentation (Agilent).

179

180 Flow cytometry analysis

181 PBMC samples were thawed in RPMI (Cytiva) complete media [L-glutamine (ThermoFisher

182 Scientific), FCS (Sigma-Aldrich), penicillin/streptomycin (Cytiva)] with DNase (Roche) and

183 counted. 3-4 million cells per sample were stained. Briefly, cells were incubated with 184 LIVE/DEAD Fixable Green Dead Cell Stain Kit (ThermoFischer Scientific) -used as a 185 viability marker- and fluorochrome-conjugated antibodies directed against surface markers 186 (Suppl Table 1) for 20 min at room temperature in the dark followed by 2 washes with flow 187 cytometry buffer (2 mM EDTA in PBS). Cells were then fixed and permeabilized using 188 FACS Lysing solution and FACS Permeabilizing solution (BD Biosciences), and next 189 incubated with intracellular staining antibodies (Suppl Table 1) for 30 min at 4°C in the dark. 190 Cells were then washed and resuspended in flow cytometry buffer. Samples were acquired 191 with a BD LSR Fortessa (BD Biosciences) flow cytometer. Flow cytometric analysis was 192 performed using FlowJo version 10.7.2 (TreeStar, Ashland). To ensure unbiased manual 193 gating, a blinded analysis was implemented, whereby all FCS3.0 files were renamed and 194 coded by one person and blindly analyzed by another person. All samples were compensated 195 electronically, and gatings were based on fluorescent-minus-one (FMO) or negative controls. 196 After all gatings were performed, samples were decoded and data analysis was performed.

197ILCs were defined as live (DCM⁻) CD1a⁻ CD14⁻ CD19⁻ CD34⁻ CD123⁻ BDCA2⁻ FcεR⁻198TCR α/β^- TCR $\gamma\delta^-$ CD3⁻ CD45⁺ CD127^{hi}. NK cells were defined as DCM⁻ CD1a⁻ CD14⁻ CD19⁻199CD34⁻ CD123⁻ BDCA2⁻ FcεR⁻ TCR α/β^- TCR $\gamma\delta^-$ CD3⁻ CD45⁺CD56⁺ CD127^{lo/hi}. For a detailed200gating strategy see Suppl Fig 1.

201

202 Multiplex immunoassay

Plasma levels of IL-5, IL-6, IL-7, IL-10, IL-13, IL-15, IL-17A, IL-18, IL-23, IL- 25, IL-33,
IFN-γ, TNF, CCL20, CCL27, CCL28, GM-CSF, TSLP, and granzyme A were measured in
plasma diluted 1:2, using a custom made Magnetic Luminex Screening assay (R&D Systems,
Minneapolis) and analysed in a Magpix instrument (Luminex), according to manufacturer's
guidelines. For graphing purposes, values not calculated by the instrument's software -

because they were out of range in the lower standard range- were replaced by half of the valueof the lowest detectable value for the given soluble factor measured.

210

211 Statistical analysis

Statistical analyses were performed using GraphPad Prism software v.9.2 for MacOSX 212 213 (GraphPad Software). Statistical differences between healthy controls and HFRS patients 214 were analyzed with Kruskal-Wallis test followed by Dunn's multiple comparison post hoc 215 test. Paired comparisons between HFRS in the different disease stages (acute, early 216 convalescence, and late convalescence) were performed using Wilcoxon test. p-values < 0.05217 were considered statistically significant. Spearman's rank correlation coefficient was used for 218 assessing correlations. Spearman's correlation matrixes were generated with R (v.4.1.1; R 219 Core Team, 2020) using package corrplot (v.0.9). Principal component analysis (PCA) was 220 performed in R (v.4.1.1) using packages Factoextra (v.1.0.7), FactoMineR (v.2.4), 221 RColorBrewer (v.1.1-2), and ggplot2 (v.3.3.5). Data was normalised in R using the scale 222 argument within the PCA function. Where data was missing, the values were imputed using 223 package missMDA (v.1.18).

224

225 **Role of the funding sources**

The funders of this study had no role in the study design, data collection, data analysis, datainterpretation, or writing of the report.

228

229 **RESULTS**

230 Study design and patient characteristics

A total of 17 PUUV-infected hospitalized HFRS patients and 10 healthy controls were

included in the study (**Table 1**). Peripheral blood samples were obtained at the acute (5-8 days

233 after onset of symptoms), early convalescent (20-27 days after onset of symptoms), and late 234 convalescent (180 or 360 days after onset of symptoms) phase of disease (Fig 1a). 235 Hospitalized HFRS patients showed a typical clinical presentation during the acute phase, 236 with thrombocytopenia, elevated C-reactive protein (CRP) and creatinine plasma levels, and 237 viral load (Table 1, Fig 1b, and Suppl Table 2). For most of the patients all parameters 238 normalized to levels within the normal range during the convalescent phase of disease (Fig 239 **1b**). The severity of the patients was assessed with a scoring system based on platelet counts, 240 creatinine values, and mean arterial blood pressure values, as previously describe. ^{61,62} Two 241 patients scored as severe, while all other scored as mild (Suppl Table 2).

242

243 HFRS patients present a strong inflammatory response during the acute phase of244 disease

245 Hantavirus disease is characterized by strong systemic inflammatory responses.^{37,40–43,64–67} 246 Using a multiplex immunoassay, we assessed the plasma levels of 19 cytokines in HFRS 247 patients during the acute and convalescent phase of disease. Except for interleukin (IL)-5, IL-248 7, and IL-17A (Suppl Fig 1a), we observed differences in levels of all proteins between acute and later stages of HFRS (Fig 2a and b). As previously reported, ^{37,40–43,64–67} the plasma levels 249 250 of tumor necrosis factor (TNF), IL-6, granulocyte-macrophage colony-stimulating factor 251 (GM-CSF), IL-10, interferon gamma (IFN- γ), IL-15, IL-18, and granzyme A (GrzA) were all 252 significantly higher in acute HFRS as compared to the convalescent phases (Fig 2b). Further, 253 we observed significantly higher levels of the type 2-associated cytokines IL-13, IL-25 (also 254 called IL-17E), IL-33, and thymic stromal lymphopoietin (TSLP), related to ILC2 and T helper 2 cell activity and involved in functions such as tissue repair.^{68,69} We also observed 255 256 significantly higher levels of the type 3-associated cytokine IL-23 in the acute phase of HFRS, involved in the activation of immune cells such as ILC3 and T helper 17 cells which 257

have a role in protection from tissue damage (Fig 2b).^{5,70} Moreover, we observed that levels
of the chemokines CCL20 and CCL27 were significantly higher in acute samples, while the
level of CCL28 was significantly decreased (Fig 2b).

261 Principal component analysis (PCA) showed that samples from the acute phase 262 separated from samples from the early and late convalescent phase. This separation was 263 mainly driven by IL-10, GrzA, IFN- γ , TNF, IL-18, CCL27 and IL-33 (Fig 2c). Interestingly, 264 patient 3, one of the two most severely ill patients in the cohort, deviated from the rest of the 265 patients, both in the acute and early convalescent phase (Fig 2c). This patient showed the 266 highest levels of several soluble factors and presented higher levels of many of them in the 267 early convalescent phase than in the acute phase (Fig 2a), suggesting a longer than usual 268 acute phase.

Additionally, we observed significant positive correlations between the type 2associated cytokines IL-25 and IL-13 and between IL-25 and TSLP during the acute phase of HFRS (**Suppl Fig 1b** and **Fig 2d and e**). Further, out of the 15 acute HFRS patients, 13 were positive for PUUV S RNA in blood and a positive correlation was seen as well between viral load and IFN-γ (**Suppl Fig 1b** and **Fig 2f**).

Altogether, these results showed that PUUV-infected HFRS patients display a strong inflammatory response, including elevated levels of 16 cytokines many of which are known to be produced by or involved in the activation of ILCs and NK cells.

277

278 Peripheral NK cells are activated but decreased in frequency during acute HFRS

We next characterized the ILC and NK cell compartments in PBMCs from HFRS patients. For the identification and analysis of ILCs and NK cells, we used 18-parameter flow cytometry and a modification of a well-established gating strategy (**Suppl Fig 2**).⁷¹

282 We observed decreased frequencies of total CD56⁺ NK cells in peripheral blood in the acute and early convalescent phase of disease, which normalized in late convalescence (Fig 283 284 **3a**). There was a decreased frequency of CD56^{dim} NK cells, with a concomitant increase of 285 the smaller population of CD56^{bright} NK cells, during the acute phase of HFRS (**Fig 3b and c**). High frequencies of CD69⁺ and HLA-DR⁺ total CD56⁺ NK cells were detected in the acute 286 287 phase of HFRS, indicating NK cell activation (Fig 3d). As expected from the general NK cell 288 activation, frequencies of NKp44⁺ and NKG2A⁺ NK cells were also increased in the acute 289 phase of HFRS (Fig 3d). Furthermore, the frequency of Ki-67⁺ NK cells was increased, 290 showing that the NK cells proliferated during acute HFRS (Fig 3d). Additionally, when 291 analyzing for homing receptors, we observed a decreased frequency of $\alpha 4\beta 7^+$ NK cells and an 292 increased frequency of CCR6⁺ and CCR10⁺ NK cells in the acute phase of HFRS (Fig 3d), 293 suggesting an effect on NK cell migration. The frequency of CD45RA⁺ and CD161⁺ NK cells 294 was decreased in HFRS patients as compared to healthy controls, with a tendency to recovery in the convalescent phase of HFRS (Fig 3d). Analysis of surface markers in the CD56^{bright} and 295 296 CD56^{dim} NK cell subsets showed similar results as observed for total NK cells (Suppl Fig 3). 297 A PCA revealed a separation of acute HFRS from convalescent HFRS patients and healthy 298 controls based on the level of expression of the different analyzed surface markers in total NK 299 cells (Fig 3e).

Next, we examined correlations between frequencies of NK cells and both soluble plasma proteins and clinical parameters (**Suppl Fig 4a-d**). IL-10 plasma levels positively correlated with the frequencies of both activated (CD69⁺) and proliferating (Ki-67⁺) NK cells (**Fig 3f and g**). Granzyme A levels correlated positively with the frequency of CD69⁺ NK cells (**Fig 3h**), and negatively with the frequency of CD161⁺ NK cells (**Fig 3i**). Interestingly, the frequency of activated (CD69⁺) NK cells correlated positively with viral load while the

frequency of total NK cells showed a negative correlation with viral load during the acutephase of HFRS (Fig 3j and k).

308

309 Peripheral ILCs are activated and proliferate during acute HFRS

310 We next characterized the peripheral ILC responses in the HFRS patients. No significant 311 difference in total ILC frequency was observed between the patients and the healthy controls 312 (Fig 4a). Interestingly, as for NK cells, we observed a negative correlation between viral load 313 and the frequency of ILCs in acute HFRS, showing reduced frequencies of peripheral ILCs in 314 patients with higher viral loads (Fig 4b). Furthermore, we observed increased frequencies of 315 activated (CD69⁺) and proliferating (Ki-67⁺) ILCs during the acute phase of HFRS (Suppl 316 Fig 5a), while no differences were observed in the frequencies of NKp44, HLA-DR, and 317 CD45RA-expressing ILCs (Suppl Fig 5a). When assessing expression of homing markers, 318 we found a decreased frequency of $\alpha 4\beta 7^+$ ILCs in acute HFRS, but no significant difference in frequencies of ILCs expressing the chemokine receptors CCR6 and CCR10 (Suppl Fig 5a). 319 320 Next, we explored specific ILC subsets. CD117^{neg} ILCs in peripheral blood have been 321 shown to make up a heterogenous population with yet undefined functions.² We therefore 322 decided to focus our analysis on the more well-defined nILC and ILC2. The composition of 323 these ILC subsets changed over time in the HFRS patients (Fig 4c). We observed an increase 324 in ILC2 frequency and a decreased frequency of naïve ILC (nILC) in the acute phase of 325 HFRS (Fig 4c and d).

326

327 Peripheral c-Kit^{lo} ILC2 are increased in frequency during HFRS

328 Next, we characterized the phenotype of the ILC subsets. Increased frequencies of activated 329 (CD69⁺) and proliferating (Ki-67⁺) nILC were observed in acute HFRS (**Fig 4e**). Moreover, 330 similar to NK cells (**Fig 3d**), a decreased frequency of $\alpha 4\beta 7^+$ nILC was observed in acute

HFRS (Fig 4e). No differences were observed in the frequencies of nILCs expressing HLADR, NKp44, CCR6, and CCR10 in HFRS patients as compared to healthy controls (Fig 4e).
PCA based on the frequency of expression of surface markers in nILC showed a separation
between the acute HFRS patients and healthy controls (Fig 4f).

335 The ILC2 population showed a similar phenotypic pattern as the nILC, with increased 336 frequency of activated (CD69⁺) and proliferating (Ki-67⁺) cells during acute HFRS (Fig 4g). 337 Additionally, a significantly decreased frequency of CCR6⁺ ILC2 was observed in the acute 338 phase of disease (Fig 4g), while no differences were observed in the frequencies of ILC2 339 expressing NKp44, HLA-DR, CCR10, and $\alpha 4\beta 7$ in HFRS as compared to healthy controls 340 (Fig 4g). In line with these findings, a PCA based on the frequency of expression of surface 341 markers on ILC2s showed no clear separation between the acute and convalescent HFRS, but 342 a separation of the acute and control samples was observed (Fig 4h). Further, when analyzing 343 for possible correlations to soluble proteins (Suppl Fig 6), we observed a positive correlation 344 between the plasma levels of IL-10 and the frequency of CD69⁺ ILC2 (Fig 4i) and between 345 plasma levels of the CCR10 ligand CCL27 and CCR10⁺ ILC2 (Fig 4j), as well as a negative 346 correlation between plasma levels of TSLP and frequency of CCR10⁺ ILC2 in acute HFRS 347 patients (Fig 4k). The first two correlations were also observed for total ILCs, as well as a 348 positive correlation between plasma levels of IL-7 and Ki-67⁺ ILC (**Suppl Fig 5b**).

Having observed an increased frequency of ILC2 (**Fig 4d**), a decreased frequency of CCR6⁺ ILC2 (**Fig 4g**), and increased plasma levels of type 2 cytokines in acute HFRS (**Fig 2**), we next assessed whether there were changes in the ILC2 subsets in HFRS patients. Indeed, we observed increased frequencies of c-Kit^{lo} ILC2 and, concomitantly, decreased frequencies of c-Kit^{hi} ILC2 during the acute phase of HFRS, as compared to convalescent HFRS patients and healthy controls (**Fig 5a and b**). Moreover, c-Kit^{hi} ILC2 showed higher frequency of CCR6 expression than c-Kit^{lo} ILC2 both in patients and healthy controls (**Fig 5c**) and,

aligning with the relative depletion of CCR6⁺ ILC2 in acute HFRS, (Fig 4g) we observed a
lower frequency of CCR6⁺ c-Kit^{hi} ILC2 in the acute phase of HFRS as compared to the
convalescent phase (Fig 5c).

359

360 **DISCUSSION**

Here we provide a detailed characterization of total ILCs, including both NK cells and nonNK ILCs, in blood samples from PUUV-infected HFRS patients. We reveal that total ILCs
are activated and show an altered composition correlating to viral load.

Whereas NK cells have been extensively described in several human viral infections ^{8–} including hantavirus infections, ^{46–49,72,73} ILCs remain understudied in human viral infections. Recent studies reveal dysregulated frequencies and phenotypes of ILCs in HIV-1,^{21,22} SARS-CoV2,^{23–25} rhinovirus,⁷⁴ and respiratory syncytial virus (RSV) infection.²⁶ Here we characterized ILCs and NK cell responses in the context of human hantavirus infection.

369 HFRS is characterized by a strong general immune activation, including 370 hyperinflammation. ^{30,75} Some typical laboratory features are leukocytosis, thrombocytopenia, 371 high CRP and hematocrit levels, and due to acute kidney injury, increased serum creatinine, proteinuria, and haematuria.^{28,31,76–78} Viral load peaks between the first 3 to 5 days during the 372 373 febrile phase of disease, and viral load is normally not detectable in the convalescent phase of 374 disease ^{31,32,79,80}. In line with this, the HFRS patients in our study presented with typical 375 laboratory findings together with a strong inflammatory response in the acute phase of disease.^{37,40–43,64–67} We observed an increase of several type 2-associated cytokines such as 376 377 IL-13, IL-25, IL-33, and TSLP in acute PUUV-infected HFRS patients. The alarmins IL-25, IL-33, and TSLP are known activators of ILC2, which upon activation can secrete IL-13.^{15,81} 378 379 These alarmins are upregulated upon infection or damage mainly of epithelial, endothelial, and stromal cells.^{82–84} Given that the main target cell of hantaviruses are endothelial cells,³⁰ it 380

is likely that hantavirus induce the secretion of the mentioned alarmins by these cells in HFRS
 patients. Interestingly, IL-33 has previously been found to be also elevated in plasma of
 Hantaan virus-infected HFRS patients and to positively correlate with disease severity.⁸⁵

As recently shown by Resman Rus and colleagues,⁴⁸ we observed transiently reduced 384 385 NK cell frequencies in peripheral blood of PUUV-infected HFRS patients, returning to normal levels during convalescence. Moreover, as earlier shown,⁴⁷ we observed that 386 387 remaining circulatory NK cells were highly proliferating, with approximately half of them 388 expressing Ki-67. During the acute phase of HFRS, NK cells also showed increased 389 expression of several activation markers and altered expression of chemokine receptors associated with migration to tissues, such as lung (CCR6) and intestine ($\alpha 4\beta 7$).^{86–89} This 390 suggests migration of NK cells to tissues, which could be the cause of the observed decreased 391 392 frequencies of NK cells in peripheral blood during acute HFRS. Interestingly, viral load 393 correlated negatively with the frequency of NK cells in peripheral blood but positively with 394 the frequency of activated NK cells, suggesting that active viral replication impacts, in an 395 unknown manner, the activation of NK cells during HFRS. We have previously shown that 396 hantaviruses have strong anti-apoptotic properties that potentially protect infected cells from 397 cytotoxic lymphocyte mediated killing and may trigger NK cell mediated bystander killing of uninfected cells.^{72,73,90,91} Whether this holds true in vivo remains to be investigated, but the 398 399 strong activation of NK cells we observe in HFRS patients could be a sign of continuous 400 attempts of NK cells to kill hantavirus-infected cells. Of further interest, we observed that 401 levels of IFN- γ also positively correlated with viral load in HFRS patients. IFN- γ is a cytokine 402 with strong antiviral effects produced by a wide array of innate and adaptive lymphocytes, including ILCs, NK cells, NKT cells, and T cells.⁹²⁻⁹⁵ The main targets of hantavirus 403 infection, such as endothelial cells and monocytes, 30,59 are not known to express IFN- γ , so this 404

405 correlation further suggests that active viral replication in infected cells indirectly leads to
406 enhanced IFN-γ production by immune cells, such as activated NK cells.

407 We observed a decreased frequency of CD161⁺ NK cells in acute HFRS patients. The 408 role of CD161 in NK cells is not fully understood, but it has been suggested to mark pro-409 inflammatory NK cells with a high ability to respond to innate cytokines.⁹⁶ There are previous 410 reports of modulation of CD161 expression in NK cells in other viral infections, such as a 411 reduced CD161 expression in NK cells in acute hepatitis C virus infection which associated 412 with enhanced viral clearance,⁹⁷ reduced frequency of CD161⁺ NK cells in Chikungunyainfected patients,98 and depletion of CD161+ NK cells in cytomegalovirus infection.96 413 414 Paralleling the findings on NK cells, downregulation of CD161 expression on MAIT cells has been described in HFRS,⁴² as well as in HIV-infected individuals.⁹⁹ Interestingly, we also 415 416 observed a negative correlation between the plasma levels of granzyme A and the frequency 417 of CD161⁺ NK cells in acute HFRS. Even though NK cells are not the sole source of 418 granzyme A in plasma, this observation could suggest that the decrease in frequency of 419 CD161⁺ NK cells - and thus increase of a CD161⁻ NK population - is related to higher NK 420 cell degranulation and cytotoxicity for viral control in HFRS patients. Along this line, we also 421 observed a positive correlation between activated NK cells and the levels of IL-10, a cytokine that has been reported to enhance the effector functions of NK cells.¹⁰⁰ 422

The frequency of ILCs is reduced in the circulation of acute HIV-infected individuals, and correlates negatively with viral load.²² In COVID-19 we also recently reported a decrease in peripheral ILC frequencies and numbers.²³ In contrast, here we did not observe a significant change in the frequency of ILCs in HFRS as compared to healthy controls. Interestingly though, and in line with the previous report for HIV infection,²² frequencies of peripheral ILCs in acute HFRS showed a strong negative correlation with viral load. Furthermore, as described for moderate COVID-19 patients,²³ acute HFRS patients presented

430 increased frequencies of ILC2 with a concomitant reduction of nILC frequencies. In contrast to our findings in COVID-19 patients,²³ we observed increased frequencies of Ki-67-431 432 expressing ILC2 and nILC in HFRS patients. Moreover, the decreased levels of $\alpha 4\beta 7^+$ nILCs 433 in acute HFRS suggest that the reduced frequency of peripheral blood nILCs could be due to 434 their migration to tissues ⁴. Alternatively, nILC might differentiate into mature ILC subsets, 435 such as ILC2s, in the circulation. Of interest, acute HFRS patients presented increased 436 frequencies of c-Kit^{lo} ILC2. Two ILC2 subsets have been defined, differing in their surface 437 expression of c-Kit and their functionality. c-Kit^{lo} ILC2 are more mature and ILC2-lineage committed, while c-Kit^{hi} ILC2 show plasticity towards an ILC3 phenotype and functionality.⁷ 438 Moreover, c-Kitlo ILC2 express less CCR6 compared to c-Kithi ILC2.7 In line with this, acute 439 HFRS patients showed decreased frequency of CCR6⁺ c-Kit^{hi} ILC2 as compared to 440 convalescent patients and healthy controls. This suggests a skewing of c-Kithi ILC2 towards 441 442 more ILC2-committed cells in HFRS, possibly explaining the increase in c-Kitlo ILC2 frequencies in acute HFRS. Alternatively, this decrease in CCR6⁺ c-Kit^{hi} ILC2 levels could 443 444 also be due to migration of these cells to lungs, where ILC2 have been shown to play an 445 important role in lung tissue repair during influenza infection in mice.^{15,16}

Here we have characterized peripheral ILCs in PUUV-infected HFRS patients. Future
characterization of ILCs in tissue samples, such as lung and intestines, can add important
knowledge regarding circulating ILC infiltration and local ILC responses.

In conclusion, this study provides the first comprehensive characterization of total circulating ILCs in hantavirus-infected patients. We report an overall activated and proliferating ILC profile in these patients, with a particular increased frequency of the ILC2 subset, and a skewing towards the ILC2-lineage committed c-Kit^{lo} ILC2 in acute HRFS. Additionally, we show that NK cells are reduced in frequencies and confirm that remaining circulating NK cells are highly activated and proliferating in acute HFRS. Moreover, we

- 455 report a negative correlation between viral load and the frequencies of both NK cells and
- 456 ILCs in acute HFRS, suggesting a potential influence of viral replication on these cells during
- 457 the acute phase of hantavirus-caused disease.
- 458

459 CONTRIBUTORS

- 460 All authors read and approved the final version of the manuscript.
- 461 MG: data curation, funding acquisition, formal analysis, investigation, methodology,
- 462 visualization, writing-original draft, writing-review & editing;
- 463 ACG: data curation, formal analysis, investigation, methodology, visualization, writing-
- 464 review & editing;
- 465 JT: methodology;
- 466 KM: methodology;
- 467 AV: resources, funding acquisition;
- 468 SM: resources, funding acquisition;
- 469 JuM: resources, funding acquisition;
- 470 ASS: resources;
- 471 TS: resources; funding acquisition;
- 472 JeM: conceptualization, investigation, visualization, writing-review & editing, supervision;
- 473 JK: conceptualization, funding acquisition, investigation, visualization, writing-review &
- 474 editing, supervision.
- 475

476 DECLARATION OF INTERESTS

- 477 The authors have no competing financial interests or conflicts.
- 478
- 479

480 ACKNOWLEDGMENTS

481	We th	hank the patients and volunteers who have contributed with clinical material to this
482	study	. We also thank Ms. Sanna Mäki for expert technical assistance. This study was
483	suppo	orted by grants from the Swedish Research Council (projects K2015-56X- 22774-01-3
484	and 2	2018-02646 to JK), Karolinska Institutet Research Foundation (project 2020-01469 to
485	MG),	the Academy of Finland (project 321809 to TS), Magnus Ehrnrooth Foundation (to
486	AV),	and Sigrid Jusélius Foundation (to AV and JuM), and the Competitive State Research
487	Finan	cing of the Responsibility Area of Tampere University Hospital (9AA050 and 9AB046
488	to Jul	M and 9AA052 to SM).
489		
490	DAT	A SHARING STATEMENT
491	The a	withors declare that the data supporting the findings of this study are available from the
492	corres	sponding authors upon reasonable request.
493		
494	REF	ERENCES
495	1.	Sonnenberg GF, Hepworth MR. Functional interactions between innate lymphoid cells
496		and adaptive immunity. Nat Rev Immunol 2019; 19: 599-613. doi:10.1038/s41577-
497		019-0194-8
498	2.	Mazzurana L, Czarnewski P, Jonsson V, Wigge L, Ringnér M, Williams TC, et al.
499		Tissue-specific transcriptional imprinting and heterogeneity in human innate lymphoid
500		cells revealed by full-length single-cell RNA-sequencing. Cell Res 2021; 31: 554-68.
501		doi:10.1038/s41422-020-00445-x
502	3.	Kokkinou E, Pandey RV, Mazzurana L, Gutierrez-Perez I, Tibbitt CA, Weigel W, et al.
503		CD45RA + CD62L – ILCs in human tissues represent a quiescent local reservoir for
504		the generation of differentiated ILCs. Sci Immunol 2022; 7: eabj8301.

21

505		doi:10.1126/sciimmunol.abj8301
506	4.	Lim AI, Li Y, Lopez-Lastra S, Stadhouders R, Paul F, Casrouge A, et al. Systemic
507		Human ILC Precursors Provide a Substrate for Tissue ILC Differentiation. Cell 2017;
508		168: 1086–100. doi:10.1016/j.cell.2017.02.021
509	5.	Vivier E, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. Innate
510		Lymphoid Cells: 10 Years On. Cell 2018; 174: 1054–66.
511		doi:10.1016/j.cell.2018.07.017
512	6.	Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. Innate
513		lymphoid cells-a proposal for uniform nomenclature. Nat Rev Immunol 2013; 13: 145-
514		9. doi:10.1038/nri3365
515	7.	Hochdörfer T, Winkler C, Pardali K, Mjösberg J. Expression of c-Kit discriminates
516		between two functionally distinct subsets of human type 2 innate lymphoid cells. Eur J
517		Immunol 2019; 49: 884–93. doi:10.1002/eji.201848006
518	8.	Jost S, Altfeld M. Control of human viral infections by natural killer cells. Annu Rev
519		Immunol 2013; 31 : 163–94. doi:10.1146/annurev-immunol-032712-100001
520	9.	Brandstadter JD, Yang Y. Natural killer cell responses to viral infection. J Innate
521		Immun 2011; 3 : 274–9. doi:10.1159/000324176
522	10.	Lam VC, Lanier LL. NK cells in host responses to viral infections. Curr Opin Immunol
523		2017; 44 : 43–51. doi:10.1016/j.coi.2016.11.003.
524	11.	Mebius RE, Rennert P, Weissman IL. Developing lymph nodes collect CD4+CD3-
525		$LT\beta$ + cells that can differentiate to APC, NK cells, and follicular cells but not T or B
526		cells. Immunity 1997; 7: 493–504. doi:10.1016/S1074-7613(00)80371-4
527	12.	Spits H, Di Santo JP. The expanding family of innate lymphoid cells: Regulators and
528		effectors of immunity and tissue remodeling. Nat Immunol 2011; 12: 21-7.
529		doi:10.1038/ni.1962

530	13.	Hildreth AD, O'sullivan TE. Tissue-resident innate and innate-like lymphocyte
531		responses to viral infection. Viruses 2019; 11. doi:10.3390/v11030272
532	14.	Stehle C, Hernández DC, Romagnani C. Innate lymphoid cells in lung infection and
533		immunity. Immunol Rev 2018; 286: 102-19. doi:10.1111/imr.12712
534	15.	Monticelli LA, Sonnenberg GF, Abt MC, Alenghat T, Ziegler CGK, Doering TA, et al.
535		Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza
536		virus. Nat Immunol 2011; 12: 1045–54. doi:10.1038/ni.2131
537	16.	Califano D, Furuya Y, Roberts S, Avram D, McKenzie ANJ, Metzger DW. IFN-γ
538		increases susceptibility to influenza A infection through suppression of group II innate
539		lymphoid cells. Mucosal Immunol 2018; 11: 209–19. doi:10.1038/mi.2017.41
540	17.	Chang YJ, Kim HY, Albacker LA, Baumgarth N, McKenzie ANJ, Smith DE, et al.
541		Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently
542		of adaptive immunity. Nat Immunol 2011; 12: 631-8. doi:10.1038/ni.2045
543	18.	Shim DH, Park YA, Kim MJ, Hong JY, Baek JY, Kim KW, et al. Pandemic influenza
544		virus, pH1N1, induces asthmatic symptoms via activation of innate lymphoid cells.
545		Pediatr Allergy Immunol 2015; 26: 780-8. doi:10.1111/pai.12462
546	19.	Li BWS, de Bruijn MJW, Lukkes M, van Nimwegen M, Bergen IM, KleinJan A, et al.
547		T cells and ILC2s are major effector cells in influenza-induced exacerbation of allergic
548		airway inflammation in mice. Eur J Immunol 2019; 49: 144-56.
549		doi:10.1002/eji.201747421
550	20.	Stier MT, Bloodworth MH, Toki S, Newcomb DC, Goleniewska K, Boyd KL, et al.
551		Respiratory syncytial virus infection activates IL-13-producing group 2 innate
552		lymphoid cells through thymic stromal lymphopoietin. J Allergy Clin Immunol 2016;
553		138: 814-824.e11. doi:10.1016/j.jaci.2016.01.050
554	21.	Krämer B, Goeser F, Lutz P, Glässner A, Boesecke C, Schwarze-Zander C, et al.

- 555 Compartment-specific distribution of human intestinal innate lymphoid cells is altered
- in HIV patients under effective therapy. *PLoS Pathog* 2017; **13**.
- 557 doi:10.1371/journal.ppat.1006373
- 558 22. Kløverpris HN, Kazer SW, Mjösberg J, Mabuka JM, Wellmann A, Ndhlovu Z, et al.
- 559 Innate Lymphoid Cells Are Depleted Irreversibly during Acute HIV-Infection in the
- 560 Absence of Viral Suppression. *Immunity* 2016; **44**: 391–405.
- 561 doi:10.1016/j.immuni.2016.01.006
- 562 23. García M, Kokkinou E, Carrasco García A, Parrot T, Palma Medina LM, Maleki KT, et
- al. Innate lymphoid cell composition associates with COVID-19 disease severity. *Clin*
- 564 *Transl Immunol* 2020; **9**: e1224. doi:10.1002/cti2.1224
- 565 24. Gomez-Cadena A, Spehner L, Kroemer M, Khelil M Ben, Bouiller K, Verdeil G, et al.
- 566 Severe COVID-19 patients exhibit an ILC2 NKG2D+ population in their impaired ILC
- 567 compartment. *Cell Mol Immunol* 2021; **18**: 484–6. doi:10.1038/s41423-020-00596-2
- 568 25. Gomes AM, Farias GB, Dias-Silva M, Laia J, Trombetta AC, Godinho-Santos A, et al.
- 569 SARS-CoV2 pneumonia recovery is linked to expansion of Innate Lymphoid Cells
- 570 type 2 expressing CCR10. *Eur J Immunol* 2021; **0**: 1–8. doi:10.1002/eji.202149311
- 571 26. Vu LD, Siefker D, Jones TL, You D, Taylor R, DeVincenzo J, et al. Elevated levels of
- 572 type 2 respiratory innate lymphoid cells in human infants with severe respiratory
- 573 syncytial virus bronchiolitis. *Am J Respir Crit Care Med* 2019; **200**: 1414–23.
- 574 doi:10.1164/rccm.201812-2366OC
- 575 27. Kuhn JH, Adkins S, Agwanda BR, Al Kubrusli R, Alkhovsky S V., Amarasinghe GK,
- 576 et al. 2021 Taxonomic update of phylum Negarnaviricota (Riboviria: Orthornavirae),
- 577 including the large orders Bunyavirales and Mononegavirales. *Arch Virol* 2021; **166**:
- 578 3513–66. doi:10.1007/s00705-021-05143-6
- 579 28. Jonsson CB, Figueiredo LTM, Vapalahti O. A global perspective on hantavirus

medRxiv preprint doi: https://doi.org/10.1101/2022.05.10.22274837; this version posted May 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license. 4837; this version posted May 14, 2022. The copyright holder for this preprint

- 580 ecology, epidemiology, and disease. Clin Microbiol Rev 2010; 23: 412-41.
- 581 29. Sabino-Santos Jr G, Goncalves F, Martins RB, Gagliardi TB, Souza WM De, Muylaert
- 582 RL, et al. Natural infection of Neotropical bats with hantavirus in Brazil. Sci Rep 2018;
- 583 8: 1-8. doi:10.1038/s41598-018-27442-w
- 584 30. Vaheri A, Strandin T, Hepojoki J, Sironen T, Henttonen H, Mäkelä S, et al.
- 585 Uncovering the mysteries of hantavirus infections. Nat Rev Microbiol 2013; 11: 539-
- 586 50. doi:10.1038/nrmicro3066
- 587 Avšič-Županc T, Saksida A, Korva M. Hantavirus infections. Clin Microbiol Infect 31.
- 588 2019; **21**: e6–16. doi:10.1111/1469-0691.12291
- 589 32. Klingström J, Smed-Sörensen A, Maleki KT, Solà-Riera C, Ahlm C, Björkström NK,
- 590 et al. Innate and adaptive immune responses against human Puumala virus infection:
- 591 immunopathogenesis and suggestions for novel treatment strategies for severe
- 592 hantavirus-associated syndromes. J Intern Med 2019; 285: 510-23.
- 593 doi:10.1111/joim.12876
- 594 33. Vaheri A, Henttonen H, Mustonen J. Hantavirus research in finland: Highlights and 595 perspectives. Viruses 2021; 13: 1452. doi:10.3390/v13081452
- 596 34. Jiang H, Du H, Wang LM, Wang PZ, Bai XF. Hemorrhagic Fever with Renal
- 597 Syndrome: Pathogenesis and Clinical Picture. Front Cell Infect Microbiol 2016; 6: 1.
- 598 doi:10.3389/fcimb.2016.00178
- 599 Liu R, Ma H, Shu J, Zhang Q, Han M, Liu Z, et al. Vaccines and Therapeutics Against 35. 600
- Hantaviruses. Front Microbiol 2020; 10. doi:10.3389/fmicb.2019.02989
- 601 36. Terajima M, Ennis FA. T cells and pathogenesis of hantavirus cardiopulmonary
- 602 syndrome and hemorrhagic fever with renal syndrome. Viruses 2011; 3: 1059–73.
- 603 doi:10.3390/v3071059
- 604 37. Sadeghi M, Eckerle I, Daniel V, Burkhardt U, Opelz G, Schnitzler P. Cytokine

605	expression	during early	v and late	phase of a	acute Puumala	hantavirus	infection	BMC
005	CAPICOSION	uuring curr	y and face	phase of c	icute i uumana	mana v m us	miccuon.	DmC

- 606 *Immunol* 2011; **12**. doi:10.1186/1471-2172-12-65
- 607 38. Linderholm M, Ahlm C, Settergren B, Waage A, Tärnvik A. Elevated plasma levels of
- 608 tumor necrosis factor (TNF)-α, soluble TNF receptors, interleukin (IL)-6, and IL-10 in
- patients with hemorrhagic fever with renal syndrome. *J Infect Dis* 1996; **173**: 38–43.
- 610 doi:10.1093/infdis/173.1.38
- 611 39. Borges AA, Campos GM, Moreli ML, Moro Souza RL, Saggioro FP, Figueiredo GG,
- 612 et al. Role of mixed Th1 and Th2 serum cytokines on pathogenesis and prognosis of
- 613 hantavirus pulmonary syndrome. *Microbes Infect* 2008; **10**: 1150–7.
- 614 doi:10.1016/j.micinf.2008.06.006
- 615 40. Saksida A, Wraber B, Avšič-Županc T. Serum levels of inflammatory and regulatory
- 616 cytokines in patients with hemorrhagic fever with renal syndrome. *BMC Infect Dis*

617 2011; **11**. doi:10.1186/1471-2334-11-142

- 618 41. Morzunov SP, Khaiboullina SF, St Jeor S, Rizvanov AA, Lombardi VC. Multiplex
- 619 Analysis of Serum Cytokines in Humans with Hantavirus Pulmonary Syndrome. *Front*
- 620 *Immunol* 2015; **6**: 432. doi:10.3389/fimmu.2015.00432
- 42. Maleki KT, Tauriainen J, García M, Kerkman PF, Christ W, Dias J, et al. MAIT cell

622 activation is associated with disease severity markers in acute hantavirus infection. *Cell*

623 *Reports Med* 2021; **2**: 100220. doi:10.1016/j.xcrm.2021.100220

- 43. Maleki KT, García M, Iglesias A, Alonso D, Ciancaglini M, Hammar U, et al. Serum
- 625 Markers Associated with Severity and Outcome of Hantavirus Pulmonary Syndrome. J
- 626 Infect Dis 2019; **219**: 1832–40. doi:10.1093/infdis/jiz005
- 627 44. Srikiatkhachorn A, Spiropoulou CF. Vascular events in viral hemorrhagic fevers: A
- 628 comparative study of dengue and hantaviruses. *Cell Tissue Res* 2014; **355**: 621–33.
- 629 doi:10.1007/s00441-014-1841-9

630	45.	Hepojoki J, Vaheri A, Strandin T. The fundamental role of endothelial cells in
631		hantavirus pathogenesis. Front Microbiol 2014; 5: 1–7. doi:10.3389/fmicb.2014.00727
632	46.	Linderholm M, Bjermer L, Juto P, Roos G, Sandström T, Settergren B, et al. Local host
633		response in the lower respiratory tract in nephropathia epidemica. Scand J Infect Dis
634		1993; 25 : 639–46. doi:10.3109/00365549309008554
635	47.	Björkström NK, Lindgren T, Stoltz M, Fauriat C, Braun M, Evander M, et al. Rapid
636		expansion and long-term persistence of elevated NK cell numbers in humans infected
637		with hantavirus. J Exp Med 2011; 208: 13-21. doi:10.1084/jem.20100762
638	48.	Resman Rus K, Kopitar AN, Korva M, Ihan A, Petrovec M, Avšič-Županc T.
639		Comparison of Lymphocyte Populations in Patients With Dobrava or Puumala
640		orthohantavirus Infection. Front Cell Infect Microbiol 2020; 10: 566149.
641		doi:10.3389/fcimb.2020.566149
642	49.	Vietzen H, Hartenberger S, Aberle SW, Puchhammer-Stöckl E. Dissection of the
643		NKG2C NK cell response against Puumala Orthohantavirus. Holbrook MR, editor.
644		PLoS Negl Trop Dis 2021; 15: e0010006. doi:10.1371/JOURNAL.PNTD.0010006
645	50.	García M, Iglesias A, Landoni VI, Bellomo C, Bruno A, Córdoba MT, et al. Massive
646		plasmablast response elicited in the acute phase of hantavirus pulmonary syndrome.
647		Immunology 2017; 151: 122–35. doi:10.1111/imm.12713
648	51.	Rasmuson J, Pourazar J, Mohamed N, Lejon K, Evander M, Blomberg A, et al.
649		Cytotoxic immune responses in the lungs correlate to disease severity in patients with
650		hantavirus infection. Eur J Clin Microbiol Infect Dis 2016; 35: 713–21.
651		doi:10.1007/s10096-016-2592-1
652	52.	Iglesias AA, Períolo N, Bellomo CM, Lewis LC, Olivera CP, Anselmo CR, et al.
653		Delayed viral clearance despite high number of activated T cells during the acute phase
654		in Argentinean patients with hantavirus pulmonary syndrome. eBioMedicine 2022; 75:

655	103765.	doi:10.1016	/j.ebiom	.2021.10)3765

- 656 53. Kerkman PF, Dernstedt A, Tadala L, Mittler E, Dannborg M, Sundling C, et al.
- 657 Generation of plasma cells and CD27–IgD– B cells during hantavirus infection is
- associated with distinct pathological findings. *Clin Transl Immunol* 2021; **10**: e1313.
- 659 doi:10.1002/cti2.1313
- 660 54. Hepojoki J, Cabrera LE, Hepojoki S, Bellomo C, Kareinen L, Andersson LC, et al.
- Hantavirus infection-induced B cell activation elevates free light chains levels in
 circulation. *PLoS Pathog* 2021; **17**. doi:10.1371/journal.ppat.1009843
- 663 55. Koma T, Yoshimatsu K, Nagata N, Sato Y, Shimizu K, Yasuda SP, et al. Neutrophil
- 664 Depletion Suppresses Pulmonary Vascular Hyperpermeability and Occurrence of
- 665 Pulmonary Edema Caused by Hantavirus Infection in C.B-17 SCID Mice. *J Virol*
- 666 2014; **88**: 7178–88. doi:10.1128/JVI.00254-14
- 667 56. Raftery MJ, Lalwani P, Krautkrämer E, Peters T, Scharffetter-Kochanek K, Krüger R,
- et al. β2 integrin mediates hantavirus-induced release of neutrophil extracellular traps.
- 669 *J Exp Med* 2014; **211**: 1485–97. doi:10.1084/jem.20131092
- 670 57. Strandin T, Mäkelä S, Mustonen J, Vaheri A. Neutrophil Activation in Acute
- 671 Hemorrhagic Fever With Renal Syndrome Is Mediated by Hantavirus-Infected
- 672 Microvascular Endothelial Cells. *Front Immunol* 2018; **9**: 2098.
- 673 doi:10.3389/fimmu.2018.02098
- 58. Marsac D, García S, Fournet A, Aguirre A, Pino K, Ferres M, et al. Infection of human
- 675 monocyte-derived dendritic cells by ANDES Hantavirus enhances pro-inflammatory
- state, the secretion of active MMP-9 and indirectly enhances endothelial permeability.
- 677 *Virol J* 2011; **8**. doi:10.1186/1743-422X-8-223
- 678 59. Scholz S, Baharom F, Rankin G, Maleki KT, Gupta S, Vangeti S, et al. Human
- hantavirus infection elicits pronounced redistribution of mononuclear phagocytes in

- 680 peripheral blood and airways. *PLoS Pathog* 2017; **13**.
- 681 doi:10.1371/journal.ppat.1006462
- 682 60. Raftery MJ, Lalwani P, Lütteke N, Kobak L, Giese T, Ulrich RG, et al. Replication in
- 683 the Mononuclear Phagocyte System (MPS) as a Determinant of Hantavirus
- 684 Pathogenicity. *Front Cell Infect Microbiol* 2020; **10**: 281.
- 685 doi:10.3389/fcimb.2020.00281
- 686 61. Vangeti S, Strandin T, Liu S, Tauriainen J, Raïsänen-Sokolowski A, Cabreraid L, et al.
- 687 Monocyte subset redistribution from blood to kidneys in patients with Puumala virus
- 688 caused hemorrhagic fever with renal syndrome. *PLoS Pathog* 2021; **17**.
- 689 doi:10.1371/journal.ppat.1009400
- 690 62. Cabrera LE, Schmotz C, Saleem MA, Lehtonen S, Vapalahti O, Vaheri A, et al.
- 691 Increased Heparanase Levels in Urine during Acute Puumala Orthohantavirus Infection
- 692 Are Associated with Disease Severity. *Viruses* 2022; **14**: 450. doi:10.3390/v14030450
- 693 63. Niskanen S, Jääskeläinen A, Vapalahti O, Sironen T. Evaluation of real-time RT-PCR
- for diagnostic use in detection of puumala virus. *Viruses* 2019; **11**.
- 695 doi:10.3390/v11070661
- 696 64. Kyriakidis I, Papa A. Serum TNF-α, sTNFR1, IL-6, IL-8 and IL-10 levels in
- hemorrhagic fever with renal syndrome. *Virus Res* 2013; **175**: 91–4.
- 698 doi:10.1016/j.virusres.2013.03.020
- 699 65. Khaiboullina SF, Levis S, Morzunov SP, Martynova E V., Anokhin VA, Gusev OA, et
- al. Serum cytokine profiles differentiating hemorrhagic fever with renal syndrome and
- 701 hantavirus pulmonary syndrome. *Front Immunol* 2017; **8**.
- 702 doi:10.3389/fimmu.2017.00567
- 703 66. Angulo J, Martínez-Valdebenito C, Marco C, Galeno H, Villagra E, Vera L, et al.
- Serum levels of interleukin-6 are linked to the severity of the disease caused by Andes

- 705 Virus. *PLoS Negl Trop Dis* 2017; **11**: e0005757. doi:10.1371/journal.pntd.0005757
- 706 67. Guo J, Guo X, Wang Y, Tian F, Luo W, Zou Y. Cytokine response to Hantaan virus
- infection in patients with hemorrhagic fever with renal syndrome. *J Med Virol* 2017;
- 708 **89**: 1139–45. doi:10.1002/jmv.24752
- 709 68. Walker JA, McKenzie ANJ. TH2 cell development and function. Nat Rev Immunol
- 710 2018; **18**: 121–33. doi:10.1038/nri.2017.118
- Kato A. Group 2 Innate Lymphoid Cells in Airway Diseases. *Chest* 2019; **156**: 141–9.
 doi:10.1016/j.chest.2019.04.101
- 713 70. Ngo VL, Abo H, Maxim E, Harusato A, Geem D, Medina-Contreras O, et al. A
- 714 cytokine network involving IL-36γ, IL-23, and IL-22 promotes antimicrobial defense
- and recovery from intestinal barrier damage. *Proc Natl Acad Sci U S A* 2018; **115**:

716 E5076–85. doi:10.1073/pnas.1718902115

- 717 71. Yudanin NA, Schmitz F, Flamar AL, Thome JJC, Tait Wojno E, Moeller JB, et al.
- 718 Spatial and Temporal Mapping of Human Innate Lymphoid Cells Reveals Elements of
- 719 Tissue Specificity. *Immunity* 2019; **50**: 505-519.e4. doi:10.1016/j.immuni.2019.01.012
- 720 72. Gupta S, Braun M, Tischler ND, Stoltz M, Sundström KB, Björkström NK, et al.
- 721 Hantavirus-infection Confers Resistance to Cytotoxic Lymphocyte-Mediated

Apoptosis. Heise MT, editor. *PLoS Pathog* 2013; **9**: e1003272.

- 723 doi:10.1371/journal.ppat.1003272
- 724 73. Braun M, Björkström NK, Gupta S, Sundström K, Ahlm C, Klingström J, et al. NK
- 725 Cell Activation in Human Hantavirus Infection Explained by Virus-Induced IL-
- 15/IL15Rα Expression. Basler CF, editor. *PLoS Pathog* 2014; **10**: e1004521.
- 727 doi:10.1371/journal.ppat.1004521
- 728 74. Dhariwal J, Cameron A, Wong E, Paulsen M, Trujillo-Torralbo MB, Del Rosario A, et
- al. Pulmonary innate lymphoid cell responses during rhinovirus-induced asthma

- exacerbations in vivo: A clinical trial. *Am J Respir Crit Care Med* 2021; **204**: 1259–73.
- 731 doi:10.1164/rccm.202010-3754OC
- 732 75. Khaiboullina SF, Martynova EV, Khamidullina ZL, Lapteva EV, Nikolaeva IV,
- 733 Anokhin V V, et al. Upregulation of IFN-γ and IL-12 is associated with a milder form
- of hantavirus hemorrhagic fever with renal syndrome. Eur J Clin Microbiol Infect Dis
- 735 2014; **33**: 2149–56. doi:10.1007/s10096-014-2176-x
- 736 76. Peters CJ, Simpson GL, Levy H. Spectrum of hantavirus infection: hemorrhagic fever
- with renal syndrome and hantavirus pulmonary syndrome. *Annu Rev Med* 1999; **50**:
- 738 531–45. doi:10.1146/annurev.med.50.1.531
- 739 77. Mustonen J, Mäkelä S, Outinen T, Laine O, Jylhävä J, Arstila PT, et al. The
- 740 pathogenesis of nephropathia epidemica: New knowledge and unanswered questions.

741 *Antiviral Res* 2013; **100**: 589–604. doi:10.1016/j.antiviral.2013.10.001

- 742 78. Jiang H, Zheng X, Wang L, Du H, Wang P, Bai X. Hantavirus infection: a global
- 743 zoonotic challenge. *Virol Sin* 2017; **32**: 32–43. doi:10.1007/s12250-016-3899-x
- 744 79. Korva M, Saksida A, Kejžar N, Schmaljohn C, Avšič-Županc T. Viral load and
- immune response dynamics in patients with haemorrhagic fever with renal syndrome.
- 746 *Clin Microbiol Infect* 2013; **19**: E358–66. doi:10.1111/1469-0691.12218
- 747 80. Pettersson L, Thunberg T, Rocklöv J, Klingström J, Evander M, Ahlm C. Viral load
- and humoral immune response in association with disease severity in Puumala
- hantavirus-infected patients-implications for treatment. *Clin Microbiol Infect* 2014; **20**:
- 750 235–41. doi:10.1111/1469-0691.12259
- 751 81. Mjösberg JM, Trifari S, Crellin NK, Peters CP, Van Drunen CM, Piet B, et al. Human
- 752 IL-25-and IL-33-responsive type 2 innate lymphoid cells are defined by expression of
- 753 CRTH2 and CD161. *Nat Immunol* 2011; **12**: 1055–62. doi:10.1038/ni.2104
- 754 82. Mindt BC, Fritz JH, Duerr CU. Group 2 innate lymphoid cells in pulmonary immunity

755		and tissue homeostasis. Front Immunol 2018; 9: 1. doi:10.3389/fimmu.2018.00840
756	83.	Fonseca W, Lukacs NW, Elesela S, Malinczak CA. Role of ILC2 in Viral-Induced
757		Lung Pathogenesis. Front Immunol 2021; 12. doi:10.3389/fimmu.2021.675169
758	84.	Rodriguez-Rodriguez N, Gogoi M, McKenzie ANJ. Group 2 Innate Lymphoid Cells:
759		Team Players in Regulating Asthma. Annu Rev Immunol 2021; 39: 167–98.
760		doi:10.1146/annurev-immunol-110119-091711
761	85.	Zhang Y, Zhang C, Zhuang R, Ma Y, Zhang Y, Yi J, et al. IL-33/ST2 Correlates with
762		Severity of Haemorrhagic Fever with Renal Syndrome and Regulates the Inflammatory
763		Response in Hantaan Virus-Infected Endothelial Cells. PLoS Negl Trop Dis 2015; 9.
764		doi:10.1371/journal.pntd.0003514
765	86.	Habtezion A, Nguyen LP, Hadeiba H, Butcher EC. Leukocyte Trafficking to the Small
766		Intestine and Colon. Gastroenterology 2016; 150: 340–54.
767		doi:10.1053/j.gastro.2015.10.046
768	87.	Lee M, Kiefel H, Lajevic MD, Macauley MS, O'Hara E, Pan J, et al. Transcriptional
769		programs of lymphoid tissue capillary and high endothelium reveal control
770		mechanisms for lymphocyte homing. Nat Immunol 2014; 15: 982. doi:10.1038/NI.2983
771	88.	Ito T, Carson WF, Cavassani KA, Connett JM, Kunkel SL. CCR6 as a mediator of
772		immunity in the lung and gut. Exp Cell Res 2011; 317: 613–9.
773		doi:10.1016/j.yexcr.2010.12.018
774	89.	Bargatze RF, Jutila MA, Butcher EC. Distinct roles of L-selectin and integrins $\alpha 4\beta 7$
775		and LFA-1 in lymphocyte homing to Peyer's patch-HEV in situ: The multistep model
776		confirmed and refined. Immunity 1995; 3: 99–108. doi:10.1016/1074-7613(95)90162-0
777	90.	Solà-Riera C, Gupta S, Maleki KT, González-Rodriguez P, Saidi D, Zimmer CL, et al.
778		Hantavirus Inhibits TRAIL-Mediated Killing of Infected Cells by Downregulating
779		Death Receptor 5. Cell Rep 2019; 28: 2124-2139.e6. doi:10.1016/j.celrep.2019.07.066

- 780 91. Solà-Riera C, García M, Ljunggren HG, Klingström J. Hantavirus inhibits apoptosis by
- 781 preventing mitochondrial membrane potential loss through up-regulation of the pro-
- 782 survival factor BCL-2. *PLoS Pathog* 2020; **16**: e1008297.
- 783 doi:10.1371/journal.ppat.1008297
- 784 92. Katze MG, He Y, Gale M. Viruses and interferon: A fight for supremacy. Nat Rev
- 785 *Immunol* 2002; **2**: 675–87. doi:10.1038/nri888
- 786 93. Samuel CE. Antiviral actions of interferons. *Clin Microbiol Rev* 2001; 14: 778–809.
 787 doi:10.1128/CMR.14.4.778-809.2001
- 788 94. Kang S, Brown HM, Hwang S. Direct antiviral mechanisms of interferon-gamma.
- 789 *Immune Netw* 2018; **18**. doi:10.4110/in.2018.18.e33
- 790 95. Kak G, Raza M, Tiwari BK. Interferon-gamma (IFN-γ): Exploring its implications in
- 791 infectious diseases. *Biomol Concepts* 2018; **9**: 64–79. doi:10.1515/bmc-2018-0007
- 792 96. Kurioka A, Cosgrove C, Simoni Y, van Wilgenburg B, Geremia A, Björkander S, et al.
- 793 CD161 defines a functionally distinct subset of pro-inflammatory natural killer cells.

794 *Front Immunol* 2018; **9**: 486. doi:10.3389/fimmu.2018.00486

- 795 97. Alter G, Jost S, Rihn S, Reyor LL, Nolan BE, Ghebremichael M, et al. Reduced
- frequencies of NKp30+NKp46+, CD161+, and NKG2D+ NK cells in acute HCV
- infection may predict viral clearance. *J Hepatol* 2011; **55**: 278–88.
- 798 doi:10.1016/j.jhep.2010.11.030
- 799 98. Petitdemange C, Becquart P, Wauquier N, Béziat V, Debré P, Leroy EM, et al.
- 800 Unconventional repertoire profile is imprinted during acute chikungunya infection for
- 801 natural killer cells polarization toward cytotoxicity. *PLoS Pathog* 2011; **7**.
- 802 doi:10.1371/journal.ppat.1002268
- 803 99. Leeansyah E, Ganesh A, Quigley MF, Sönnerborg A, Andersson J, Hunt PW, et al.
- 804 Activation, exhaustion, and persistent decline of the antimicrobial MR1-restricted

- 805 MAIT-cell population in chronic HIV-1 infection. *Blood* 2013; **121**: 1124–35.
- 806 doi:10.1182/blood-2012-07-445429
- 807 100. Wang Z, Guan D, Huo J, Biswas SK, Huang Y, Yang Y, et al. IL-10 Enhances Human
- 808 Natural Killer Cell Effector Functions via Metabolic Reprogramming Regulated by
- 809 mTORC1 Signaling. *Front Immunol* 2021; **12**: 366. doi:10.3389/fimmu.2021.619195

810

811 FIGURE LEGENDS

812 **1.** Cohort design and clinical characterization of PUUV-infected hemorrhagic fever with

813 renal syndrome (HFRS) patients.

- 814 (a) Schematic overview of peripheral blood sample collection in control subjects (n=10) and
- 815 PUUV-infected HFRS patients (n=17) at acute (5 to 8 days), early convalescence (20 to 27
- 816 days), and late convalescence phase (180- or 360-days post onset of symptoms).
- (b) Levels of platelets ($10^{9}/L$), creatinine (μ mol/L), C-reactive protein (CRP, mg/L), and copy
- 818 numbers of PUUV S RNA in plasma (10^4 /ml) in acute (n=14), early convalescence (n=15),
- 819 and late convalescence (n=17) phase. Dotted lines indicate reference values in healthy adults.
- Graphs show data of individual subjects (circles) and the median (bars) \pm interquartile range. Statistical significance was assessed using the Wilcoxon signed-rank test. Severe patients are indicated by a black circle. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
- 823

824 **2.** Altered levels of soluble factors in peripheral blood of HFRS patients.

(a) Heatmap displaying the normalized plasma concentration of each soluble factor in each
HFRS patient at acute, early convalescent, and late convalescent phase, as measured by
multiplex immunoassay. Colors depict high (red) or low (blue) concentration. Values were
normalized dividing each one by the highest value obtained for the given soluble factor.

(b) Level of soluble factors in plasma of HFRS patients in acute (n=15), early convalescence

- (n=16), and late convalues cence (n=17) phase.
- 831 (c) Principal component analysis (PCA) displaying the distribution of HFRS patients832 according to the plasma level of soluble factors.
- 833 (**d-f**) Spearman rank correlation between plasma levels of (**d**) IL-25 and IL-13, (**e**) IL-25 and
- 834 TSLP, and (f) IFN- γ and viral load in acute HFRS patients (n=15).

Abbreviations: IFN- γ : interferon gamma; IL: interleukin; TNF: tumor necrosis factor alpha; TSLP: Thymic stromal lymphopoietin; GM-CSF: granulocyte-macrophage colonystimulating factor; CCL: chemokine ligand. Graphs show data of individual subjects (circles) and the median (bars) \pm interquartile range. Statistical significance was assessed using the Wilcoxon signed-rank test. Severe patients are indicated by a black circle and patient 3 is labeled as P03. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.

841

842 3. NK cells are activated, proliferative and decreased in frequency in peripheral blood of 843 HFRS patients.

(a) Percentage of NK cells out of CD45⁺ lymphocytes (Ly) in control donors (n=10) and
HFRS patients during the acute (n=15), early convalescence (n=16), and late convalescence
(n=17) phase.

(b) Representative flow cytometry plots showing percentage of CD56^{bright} and CD56^{dim} NK
cells (gated as CD3⁻CD56⁺ cells as in Fig S2) in a control donor and in an HFRS patient. (c)
Percentage of CD56^{bright} and CD56^{dim} NK cells of CD3⁻CD56⁺ cells in control donors (n=10)
and HFRS patients during the acute (n=15), early convalescence (n=16), and late
convalescence (n=17) phase.

852 (d) Percentage of CD69⁺, Ki-67⁺, HLA-DR⁺, NKp44⁺, NKG2A⁺, CCR6⁺, CCR10⁺, α 4 β 7⁺, 853 CD45RA⁺, and CD161⁺ NK cells of total CD3⁻CD56⁺ cells in control donors (n=10) and 854 HFRS patients during the acute (n=15), early convalescence (n=16), and late convalescence

855 (n=17) phase.

- (e) Principal component analysis (PCA) of total CD3⁻CD56⁺ NK cells in healthy controls and
 HFRS patients displaying the contribution of NK cell surface markers indicated in (d). Each
- 858 dot represents one donor.

(f-k) Spearman rank correlation between plasma IL-10 levels and the percentage of (f) CD69⁺
NK cells and g. Ki-67⁺ NK cells, between plasma granzyme A (GrzA) levels and the
percentage of (h) CD69⁺ NK cells and (i) CD161⁺ NK cells, and between plasma viral load
(n=13; PUUV S RNA copies/mL) and the percentage of (j) NK cells out of CD45⁺
lymphocytes and (k) CD69⁺ NK cells in acute HFRS patients.

- Bar graphs are shown as mean and lines connect paired samples from the same patient. Statistical significance was assessed using the Wilcoxon signed-rank test to compare groups of HFRS patients, and the Kruskal-Wallis test followed by Dunn's multiple comparisons test to compare healthy controls with groups of HFRS patients. Severe patients are indicated by black circles. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
- 869

4. ILCs display an activated and proliferative profile in peripheral blood of HFRS
patients.

- (a) Percentage of ILCs (gated as Lin⁻CD3⁻CD127^{hi} as in Fig S2) out of CD45⁺ lymphocytes
 (Ly) in control donors (n=10) and HFRS patients during the acute (n=15), early
 convalescence (n=16), and late convalescent (n=17) phase.
- (b) Spearman rank correlation between plasma viral load (PUUV S RNA copies/mL) and the
 percentage of ILCs out of CD45⁺ lymphocytes in acute HFRS patients (n=15).

877 (c) Representative flow cytometry plots showing percentage of ILC2 and naïve ILC (nILC) in

- a control donor and in an HFRS patient (gated on ILCs as in Fig S2). (d) Percentage of ILC2
- and nILC in control donors (n=10) and HFRS patients during the acute (n=15), early convalescence (n=16), and late convalescence (n=17) phase.
- 881 (e) Percentage of CD69⁺, Ki-67⁺, HLA-DR⁺, NKp44⁺, CD56⁺, CCR6⁺, CCR10⁺, $\alpha 4\beta 7^+$, and
- 882 CD45RA⁺ nILC in control donors (n=10) and HFRS patients during the acute (n=15), early
- 883 convalescence (n=16), and late convalescence (n=17) phase. (f) Principal component analysis

884 (PCA) of nILC in control donors and HFRS patients displaying the contribution of nILC 885 surface markers indicated in (e). (g) Percentage of CD69⁺, Ki-67⁺, HLA-DR⁺, NKp44⁺, 886 CD56⁺, CCR6⁺, CCR10⁺, α4β7⁺, and CD45RA⁺ ILC2 in control donors (n=10) and HFRS 887 patients during the acute (n=15), early convalescence (n=16), and late convalescence (n=17)888 phase. (h) PCA of ILC2 in control donors and HFRS patients displaying the contribution of 889 ILC2 surface markers indicated in (g). (i-k) Spearman rank correlation between (i) plasma IL-890 10 levels and the percentage of CD69⁺ ILC2, (j) plasma CCL27 levels and the percentage of 891 CCR10⁺ ILC2, and (k) plasma TSLP levels and the percentage of CCR10⁺ ILC2 in acute 892 HFRS patients (n=15).

Bar graphs are shown as mean and lines connect paired samples from the same patient. Statistical significance was assessed using the Wilcoxon signed-rank test to compare groups of HFRS patients, and the Kruskal-Wallis test followed by Dunn's multiple comparisons test to compare healthy controls with groups of HFRS patients. Severe patients are indicated by a black circle. Patients with low cell numbers (fewer than 20 events) in the corresponding gate were removed from the analysis. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.

900

901 5. Increased ILC2 c-Kit^{lo} frequency in peripheral blood of acute HFRS patients.

902 (a) Representative flow cytometry plots showing percentages of c-Kit^{lo} and c-Kit^{hi} ILC2 in a 903 control donor and in an HFRS patient (gated on total ILC2 as in Fig S2). (b) Percentage of c-904 Kit^{lo} and c-Kit^{hi} ILC2 in control donors (n=10) and HFRS patients during the acute (n=15), 905 early convalescence (n=16), and late convalescence (n=17) phase. (c) Percentage of CCR6⁺ c-906 Kit^{lo} and CCR6⁺ c-Kit^{hi} ILC2 in control donors (n=10) and HFRS patients during the acute 907 (n=15), early convalescence (n=16), and late convalescence (n=17) phase.

908	Bar graphs are shown as mean and lines connect paired samples from the same
909	patient. Statistical significance was assessed using the Wilcoxon signed-rank test to compare
910	groups of HFRS patients, and the Kruskal-Wallis test followed by Dunn's multiple
911	comparisons test to compare healthy controls with groups of HFRS patients. Severe patients
912	are indicated by a black circle. Patients with low cell numbers (fewer than 20 events) in the
913	corresponding gate were removed from the analysis. $p < 0.05$; $p < 0.01$; $p < 0.01$; $p < 0.001$.

Table 1. Clinical and laboratory characteristics of donors.

Characteristic	HFRS patients	Healthy controls	
n° of patients / controls	17	10	
Age (years), median (IQR)	35(28.5-51)	47.5 (38.25-53.25)	
Gender (female), n° (%)	12 (71)	2 (20)	
Viral load at time of sampling (PUUV S RNA copies/mL), median (IQR)	94,272 (47,300-187,975)	ND	
Platelet count (x 10 ⁹ /L), median (IQR)	97 (85-119)	ND	
CRP (mg/L), median (IQR)	58.2 (33.4-93.5)	ND	
Creatinine (µmol/L), median (IQR)	146 (96-298)	ND	
Days after symptoms onset, median (IQR)	6 (6-8)	NA	
Days hospitalized, median (IQR)	5 (4 - 6.5)	NA	
Hematocrit (L/L) median (IQR)	0.37 (0.37-0.41)	ND	
PCR positivity CMV, n° (%)	0 (0)	ND	
PCR positivity EBV, n° (%)	1 (6)	ND	

NA: not applicable; ND: not determined; IQR: interquartile range; CRP: C-reactive protein; CMV: cytomegalovirus; EBV: Epstein-Barr virus

Platelet count; normal range 150-360 x10^9/L.

Plasma CRP; reference <3 mg/L.

Plasma creatinine; reference <90 $\mu mol/L$ for women, <100 $\mu mol/L$ for men.



а

redRxiv preprint doi: https://doi.org/10.1101/2022.05.10.22274837; this version posted May 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



IL-25 (pg/mL)

Viral load (PUUV S RNA copies/mL)

IL-25 (pg/mL)







С

